Search results
Results from the WOW.Com Content Network
Here are five low-risk drugs that the FDA could make available over the counter today. (Illustration: Wikimedia) Albuterol: Research shows that albuterol is vastly superior at relieving asthma ...
Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, [1] is a medication that opens up the medium and large airways in the lungs. [8] It is a short-acting β 2 adrenergic receptor agonist that causes relaxation of airway smooth muscle . [ 8 ]
The drug policy of the Philippines is guided by the Comprehensive Dangerous Drugs Act of 2002 and is implemented by the Dangerous Drugs Board with its implementing arm, the Philippine Drug Enforcement Agency along with other member agencies. Aside from regulating and prohibiting the usage, sale, production of certain drugs, the 2002 law is ...
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
Clenbuterol is approved for use in some countries as a bronchodilator for asthma. [medical citation needed]Clenbuterol is a β 2 agonist with some structural and pharmacological similarities to epinephrine and salbutamol, but its effects are more potent and longer-lasting as a stimulant and thermogenic drug.
Concomitant administration of bambuterol with corticosteroids, diuretics, and xanthine derivatives (such as theophylline) increases the risk of hypokalemia (decreased levels of potassium in the blood).
Azelastine, sold under the brand name Astelin among others, is a H 1 receptor-blocking medication primarily used as a nasal spray to treat allergic rhinitis (hay fever) and as eye drops for allergic conjunctivitis.
For third-line treatments, middle- and high-income countries have also faced challenges of expensive drug prices. In the US, the cost of third-line treatment was 41% greater than the cost of first-line treatment, at respective prices of $40,804 per patient per year and $28,861 per patient per year in 2013. [14]